Werewolf Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$1.27next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly46.5M
Quarterly Net Loss Quarterly-13.5M
Quarterly Research and Development (R&D) Expenses Quarterly8.2M
Watch Items
- Strategic Review and Restructuring ProcessTrigger: Execution of a merger, acquisition, asset sale, or strategic partnershipAction: Evaluate transaction terms, valuation, and impact on shareholder equity
- WTX-124 Clinical Development and PartneringTrigger: Securing a strategic partner for Phase 2/registral developmentAction: Assess partnership economics, upfront payments, and milestone structures
- WTX-330 Clinical Development and PartneringTrigger: Securing a strategic partner for further clinical developmentAction: Assess partnership economics and clinical development path
- Preclinical IND Filings for INDUCER Platform (WTX-1011 and WTX-2022)Trigger: IND submissions planned by mid-2027Action: Monitor preclinical progress and timeline adherence
Research as of 19 Jun 2026